



## PRESS RELEASE

### Successful financing round

## TNI medical: more capital for innovative respiratory disease treatment

**Würzburg/Tübingen, October 6, 2015. The medical technology company TNI medical is receiving further funding in a second financing round. Two new investors - the Portuguese investment firm Pathena and a private investor - are investing in the Würzburg based company. The existing investors, SHS Gesellschaft für Beteiligungsmanagement and KfW, will be retaining shares. TNI medical is a leading provider of innovative treatment methods for patients with chronic obstructive pulmonary disease (COPD) and respiratory complaints.**

In order to help patients with respiratory problems following a hospital stay, TNI medical has developed a product for respiratory support that can even be used at home - the TNI Softflow. Therapy with Nasal Insufflation (TNI) consists of supplying the patient with a constant, warm, humid flow of air, which can also be enriched with oxygen if needed. This innovative treatment method not only achieves excellent clinical results, but also provides patients with an increased level of comfort as compared to traditional mask therapy. In addition to this, initial clinical trials indicate higher survival rates in the treatment of patients with acute respiratory diseases. The funds from the new financing round will be used to enable the market launch of TNI Softflow both within Germany and abroad. The financing will primarily be used to conduct clinical trials and obtain international approvals.

According to expert forecasts, the number of patients with respiratory diseases, and COPD in particular, is on the rise around the world. There is an increasing need for effective and, above all, comfortable treatment methods. The closed nose and face masks, which currently serve as the "gold standard" in this area, are only used reluctantly by many patients if at all.

"We are very pleased to have an increased number of investors for TNI. The success of this financing round and the major investment of a Portuguese investor indicate a great interest in our respiratory support devices across Europe", says Ewald Anger, CEO of TNI medical AG.

"We analyzed numerous medical technology companies internationally in the chronic space. We chose to invest in TNI medical because we are convinced that TNI medical is active in a growing market and can help many patients, and especially those with chronic respiratory diseases", explains António Murta, Managing Partner of Pathena.

"With this subsequent financing, TNI medical will be able to focus on achieving further milestones towards launching its products both within Germany and around the world. We are looking forward to continuing to support the company along its successful path together with the company's management team", says Reinhilde Spatscheck, Managing Partner at SHS.

#### **About TNI medical AG**

TNI medical AG is based in Würzburg, Germany and focuses on the development, production, and sale of respiratory treatment and diagnostics devices. Therapy with Nasal Insufflation (TNI) was developed for intensive care and hospital applications as well as home use. With its recently introduced TNI® softFlow systems, TNI medical AG is focusing respiratory support on maximizing patient comfort while simplifying use. This has the added benefit of improved cost effectiveness.

*Further information: [www.tni-medical.de](http://www.tni-medical.de)*

#### **About Pathena:**

PATHENA is a Venture Firm focused on boosting the success of Information Technology and Medtech companies with strong IP based solutions. Pathena Fund is focused in late early stage and growth companies, with €56m committed and holds minority stakes in the invested companies.

Pathena's investment strategy is centered on solutions that address chronic conditions, affordable diagnostics and medical cloud.

Portuguese and international investors include the European Investment Fund, funds of funds, entrepreneurs and the Pathena management team.

As Key Opinion Leader and reference in the IT and Medtech sectors Pathena has privileged access to prime deal-flow, universities and decision makers. The team has an entrepreneurial background of founding, growing and exiting companies, and is working together for more than 12 years.

António Murta and Jorge Brás are the Managing Partners at Pathena.

*Further information: [www.pathena.com](http://www.pathena.com)*

**Further information:**

Tel.: +351 225 430 707

[info@pathena.com](mailto:info@pathena.com)

Edifício Península, sala 602

Praça do Bom Sucesso, nº131

4150-456 Porto - Portugal

**About SHS Gesellschaft für Beteiligungsmanagement mbH:**

SHS Gesellschaft für Beteiligungsmanagement is based in Tübingen, Germany and invests in medical technology and life science companies with a focus on growth financing, changes in shareholder structures and successor situations. SHS holds minority as well as majority shares. SHS was founded in 1993 and has since gained extensive experience as industry investor, which supports the growth of its portfolio companies through a network of partnerships regarding the introduction of new products, regulatory issues or entering new markets. The SHS funds' German and international investors include the European Investment Fund, professional pension funds, retirement funds, funds of funds, family offices, entrepreneurs and the SHS management team. The AIFM-registered company is currently investing from its fourth generation of funds, for which investors have provided more than 125 million euro. The fund provides equity investments of up to 20 million euro. Transactions can be carried out in the mid double-digit million range together with a network of co-investors. Reinhilde Spatscheck, Dr. Bernhard Schirmers, Hubertus Leonhardt and Uwe Steinbacher are the Managing Partners at SHS.

[Here](#) you find an overview of SHS's current portfolio companies.

*Further information: [www.shsvc.net/en](http://www.shsvc.net/en)*

**Further information:**

Dr. Reinhard Saller

Ira Wülfing Kommunikation GmbH

Tel.: +49 (0)89 2000 30 38

Fax: +49 (0)89 2000 30 40

[reinhard.saller@wuelfing-kommunikation.de](mailto:reinhard.saller@wuelfing-kommunikation.de)